Indian Patents. 252551:DIAMINO PYRIMIDINE CARBONITRILE DERIVATIVES AND THEIR MEDICINAL APPLICATIONS

Title of Invention	DIAMINO PYRIMIDINE CARBONITRILE DERIVATIVES AND THEIR MEDICINAL APPLICATIONS
Abstract	The present invention provides novel Diamino pyrimidine carbonitrile derivatives of general formula/structure (I) and a method for preparing general structure/compounds (I.) The compounds, derivatives and analogs thereof, are useful treatment, management, or prevention of, or amelioration of one or more symptoms of cancer, HIV, tuberculosis and other microbial and viral infections.

Full Text	FORM 2 The Patent Act 1970, (39 of 1970) & The Patent rule 2003 COMPLETE SPECIFICATION (See Section 10 and Rule 13) 1. TITLE OF THE INVENTION Diamino pyrimidine carbonitrile derivatives and their medicinal applications 2.APPLICANT (S) (a) NAME: (b) NATIONALITY: (c) ADDRESS: Shelar Ashok Ranganath Indian Dr.Ashok Shelar (Ph.D) Plot No.8,Unit No.1 Ambai Defence Colony, Kolhapur-416008 Maharashtra State(lndia) 2. COMPLETE SPECIFICATION DESCRIPTION The following specification particularly describes the invention and the manner in which it is to be performed. TITLE Diamino pyrimidine carbonitrile derivatives and their Medicinal applications Field of Invention: Heterocyclic compounds occur widely throughout the nature; indeed, probably the majority of known organic compounds are heterocyclic in structure. The pyrimidine ring system occurs in thymine,cytosine,uracil, adenine and guanine which are component structures of nucleic acids and certain coenzymes. Pyrimidine nucleosides have an important role in medicinal chemistry. Many antibiotics are nucleosides of pyrimidines which are effective in halting growth of cancer and can inhibit growth or destroy microorganisms ex.Puromycins. Many pyrimidines of synthetic origin are widely used as therapeutic drugs, of these is a sulfonamide drug, sulfadiazine.Other class of pyrimidine medicinals are barbituric acid and phenobarbitals. Literature is replete with medicinal uses of pyrimidines and purines.For instance 2, 6-dimercapto purines are used as anticancer agents. References: D.J.Brown, "The Pyrimidines" Wiley (Interscience), New York, 1962 T.L.V.Ulbricht, "Purines,Pyrimidines and Nucleotides" Pergamon, Oxford, 1964 PRIOR ART OF INVENTION Diaminopyrimidine carbonitriles: Among different derivatives of pyrimidines,the aminopyrimidines play very important role in the biological processes.The nucleic acids have pyrimidines in different forms. The pyrimidine derivatives show profound physiological activities. Particularly the the pyrimidine carbonitriles show a wide spectrum of biological activity including antiviral,antibacterial,antitumor and antiinflammatory. REFERENCES(Synthesis) 1. P.Biginelli, Gazz.Chim.Ital.,23,360,1893 2. C.O.Kappe, Tetrahedron,49,6937,1993 3. C.O.Kappe, Acc,Chem.Res.,33,879,200 ANTIBACTERIAL ACTIVITY 1 .T.Matsuda,I.Hirao,Nippon Kagaku Zasshi,86,l 195,1965 ANTI HIV ACTIVITY: A.D.Patil et al. J.Org.Chem.,6,1182,1995 ANTI CANCER ACTIVITY 1. J.Med.Chem.,Vol.50,Nol9,Page 4728,2007 2 .E.N.Dozorova et al., Pharm.,19,154,1985 3 E.Buchdunger J.et al., Cancer Res.,56,100,1996 4. E.Maquoi et al., Clin,Cancer Res.,10,4038,2004 5. 5.M.Huang et al., Mol.Pharmacol,62,463,2002 STATEMENT OF INVENTION (OBJECT OF INVENTION) There is ever present need for efficacious,nontoxic,with least side effects, drugs against a variety of human diseases. Alleviation of human sufferings has to be the primary aim of every scientific endevour, particularly in the fields of drug discovery.Towards this end an attempt is being made to provide novel drug molecules that have immense potential of treatment and cure against infectious diseases and deadly forms of cancer as also viral infections like HIV. DESCRIPTION OF INVENTION IN DETAIL: The compounds of following general formula/structure ( I ) have been prepared. PROCEDURE FOR PREPARING COMPOUNDS OF GENERAL FORMULA (I) H2N N NH2 General structure / formula (I) Suitably substituted benzaldehyde( 10 m mole ),malonitrile ( 10 mmole and potassium carbonate ( 1 gm ) were taken in a 500 ml round bottom flask with suitable quantity of water and agitated thoroughly. Then was added guanidine hydrochloride (20 m mole) and catalytic amount of tetrahydro butyl ammonium bromide (TBAB) and the contents were refluxed until the reaction was complete as indicated on TLC run. On work up the desired product was obtained which was recrystallized from a suitable combination of ethanol and water. The structures of compounds were checked and confirmed by spectroscopic and physical characterization.. 2,4-diamino-6-(4-hydroxy phenyl) pyrimidine-5-carbonitrile IR 3308 cm -1,3210 cm-1 (OH and NH2),221a9cm-1(CN),1644cm-1, 1588cm-l(aromatic double bonds) PMR singlet d 2.49,3.62 (two NH2 protons), doublet of doublet at d 6.84 and another at d 7.23-8.04 (aromatic protons) C13 NMR 75.1,115.1,122.8.130.1,133.8,157.8,158.9,160.5&113.9 Elemental Analysis C11H9 N5 O Observed C 58.16%, H 4.00%, N 30.84% Melting Point 260 degree centigrade Structures and IUPAC Names of Compounds IUPAC Chemical Names Structure No 2.4-diamino-6-(2-hydroxy phenyl) pyrimidine-5-carbonitrile 1 2,4-diamino-6-(4-hydroxy phenyl) pyrimidine-5-carbonitrile 2 2,4-diamino-6-(3,4-dimethoxy phenyl) pyrimidine-5-carbonitrile 3 2,4-diamino-6-(4-methoxy phenyl) pyrimidine-5-carbonitrile 4 2,4-diamino-6-(4-chloro phenyl) pyrimidine-5-carbonitrile 5 2,4-diamino-6-(4-fluoro phenyl) pyrimidine-5-carbonitrile 6 BIOLOGICAL ACTIVITY PROFILE FOR THE COMPOUNDS: Following Methods have been employed for screening for biological activities. Antimicrobial activities were determined by the Microbroth Dilution Method ( NCCLS ) Anti Tubercular activities were determined against the H 37 Rv strain of M.tuberculosis Cyto toxic effects was evaluated using the human HeLa cell line stfteured from the National Center For Cell Science,Pune Anti retro viral tests for evaluation of anti HIV activity was performed by the Method of Viral Load by RT-PCR The details of procedure are given in the following pages Determination of Minimum Bactericidal Concentration: Microbroth Dilution Method(NCCLS) Materials and Reagents Mueller-Hinton broth for performance of MIC test 1.0 and 0.5 McFarland turbidity standards Scrupulously clean,acid washed borosilicate glass tubes Vortex mixer Eppendrof or similar micropipette Nutrient agar plates.such as blood agar,for subculture fro broth PROCEDURE Preparation of Inoculation Subcultured the test organism and quality contro organisms into Appropriate medium(a blood agar plate)and incubated overnight at 35C Inoculate a tube that contains 2 ml of saline or Mueller-hinton broth With five or more colonies from the agar plate and adjust turbidity to Match a McFarland standard(approximately 10 CFU/ml) Transfer 0.1 ml of the turbid broth into 10 ml of Mueller-Hinton Broth,inoculate in shaking water bath or equivalent at 35C until Turbid(5 to 6 hours for rapid growth) .The relevant control organism Should be inoculated into 3 ml of broth and incubated without shaking Until turbid.This represents a midexponential phase of growth. Prepare twofold serial dilutions of the antibiotic in 2 ml of Mueller-Hinton broth.Use acid washed borosilicated glass tubes. Standardise the inoculum of the patients organism and the control Strain by adjusting to a McFarland 0.5 standard in 3 ml of saline broth. Dilute the adjusted inocula 1:10(approx 5X10 CFU/ml) Using an Eppendorf or equivalent pipette,dispence 0.1 ml of the diluted Inoculum intothe tubes that contain serial dilutions of antibiotic.Insert the Tip well under the surface of the broth;avoid any contact between the tip and the walls of the tube.Rinse the tip five times.The same tip may be used If the tubes are inoculated from the lower to higher concentration of the antibiotic.The final inoculum size is approximately 2.5X10 CFU/ml. incubate the tubes for 20 hours at 35C. QUANTITATION OF THE INOCULUM From the final dilution of the inoculum(approximately 5X10 CFU/ml) perform four serial tenfold dilutions in Mueller-Hinton broths (final Concentration of 5X10 CFU/ml). In duplicate dispense 0.1ml onto the surface of a blood agar plate.Spread the inoculum evenly with sterile bent glass rod. incubate the plates overnight at 35C. DETERMINATION OF MIC After overnight incubation determine the MIC of quantity control strain by virtual inspection of the tubes. For the patient's sample only,vortex the tubes without growth vigorously for 15 seconds to resuspend any bacteria that might have adhered to the walls of the tube(avoid aerosols). reincubate the tubes for additional four hours. Determine the MIC of patient's sample by visual inspection of the tubes. CONCLUSIONS: The compounds of General Formula (I) have shown excellent activity against Staph.Aureus,E-Coli.Klebsiella,Enterococcusfecalis.Antifungal activity against Fluconazole Aspergillus and Candida albicas. Anti T.B. tests Anti tubercular activity was tested against H37 Rv strain of M.tuberculosis maintained in the laboratory.Middle brook 7H9 medium was prepared in bottles and starilised by autoclaving.ADC growth supplement containing bovine albumin fraction V,dextrose and catalase was added to each bottle with sterile precautions. A sterile suspension(10 mg/ml) of each compound to be tested was prepared using appropriate solvents under sterile conditions.Each compound was tested at a concentration say of 5 micro grams/ml and the required amount was added to each bottle of middle brook medium.M.tuberculosis culture suspension was added at a concentration of 10 raise to 5 organisms per ml and the media were incubated at 37 degree centigrade in a humidified chamber for at least 4 weeks. Controls of antimycobacterial agents i.e. ciprofloxacin 5micro grams/ml,streptomycin 7.5 micro grams/ml and pyrazinamide 7.5 micro grams /ml were set up with each batch.A medium control and growth control tubes also were included. Each bottle was examined periodically to observe for growth or contamination if any.At the end of four weeks a smear was prepared from each bottle showing turbidity stained with Z-N stain to confirm the presence of M.tuberculosis.Those media with the presence of organisms were considered as resistant to the compound and those without any bacteria were deemed as sensitive. CONCLUSIONS: The compounds of General Formula (I) have shown excellent activity against the H37 Rv strain of M.Tuberculosis.The lab results were further confirmed by field tests on Actual samples from patients. Anti Cancer Tests In vitro evaluation of cytotoxic effects on human tumour cell lines: Cell culture. The HeLa cell line(procured from National Centre For Cell Science Pune University,India)was maintained in the labs by serial sub cultures. The cell line was maintained as mono layers in 75 cm square culture flasks in Eagles minimum essential medium supplemented with 10% fetal calf serum 2mg of gentamicin, 100 Unit/ml of penicillin and 100 micro gram/ml of streptomycin. The cells were grown in humidified 37 degree incubator with a regulated supply of 5% carbon dioxide. Medium was changed every 5-6 days. On the day of the experiment cells were washed with phosphate buffered saline and were detached from the surface of the flask by addition of 0.25% trypsin in EDTA buffer.The cells were then plated at a density of 5X10 to the power of 3 cells per well in 96 well micro plates containing 250 micro litre of cell culture medium per well and allowed to adhere over night. Stock solutions(10 micro gram per ml) of the compounds to be tested were freshly prepared just before use under sterile conditions. Each compound was tested in two concentration 10 and 100 micro grams per ml.Requisite amount of the compound was added to each well and were allowed to act on tumour cells for a period of 72 hours. A cell control was also set up with each compound for comparison. At the end of the incubation period, each well was studied under 40X power inverted microscope and analyzed for cytotoxic effects of each concentration of the compound on tumour cell lines. CONCLUSIONS: The compounds of General Formula (I) have shown excellent anti cancer activity.The Photographs are records of the cell growth inhibition. WE CLAIM: 1. A process for the preparation of compounds of the general formula (I) 2. A process of the claim 1, wherein suitably substituted benzaldehyde (l0mmole), malonitrile (l0mmole), potassium carbonate (0.5 g) and water (40 ml) are mixed well; 3. A process of the claim 2, wherein guanidine hydrochloride (15mmole) and pinch of tetrabutyl ammonium bromide(TBAB) are added and refluxed. 4. A process of the claim 1, wherein the substituents are, as Rl=H,OH,OMe,Cl,F,N02 etc. R2=H,OH,OMe,Cl etc R3=H,OH,C1 etc. 5. A method for inhibiting the growth of pathogenic microorganisms (ex: bacteria,fungi,M.tuberculum etc.) wherein the chemotherapeutic agent is a compound of general formula ( I ), its salt or a pharmaceutically acceptable form. 6. A method for inhibiting the growth/replication of any form of cancer (ex: tumor etc) wherein the chemotherapeutic agent is a compound of the general formula ( I ),its salt or a pharmaceutically acceptable form. 7. A method for inhibiting the replication of viruses (ex:HIV etc) wherein the chemotherapeutic agent is compound of the general formula ( I ),its salt or a pharmaceutically acceptable form. 8. A method for use as CNS stimulant( ex: Nootropic or Alzheimer agent) wherein the chemotherapeutic agent is a compound of the general formula ( I ),its salt or a pharmaceutically acceptable form. ABSTRACT The present invention provides novel Diamino pyrimidine carbonitrile derivatives of general formula/structure ( I ) and a method for preparing general structure/compounds ( I.) The compounds,derivatives and analogs thereof, are useful for treatment,management,or prevention of, or amelioration of one or more more symptoms of cancer, HIV , tuberculosis and other microbial and viral infections.

Full Text

FORM 2
The Patent Act 1970,
(39 of 1970)
&
The Patent rule 2003
COMPLETE SPECIFICATION
(See Section 10 and Rule 13)
1. TITLE OF THE INVENTION
Diamino pyrimidine carbonitrile derivatives and their medicinal applications

2.APPLICANT (S)
(a) NAME:
(b) NATIONALITY:
(c) ADDRESS:

Shelar Ashok Ranganath Indian

Dr.Ashok Shelar (Ph.D) Plot No.8,Unit No.1 Ambai Defence Colony, Kolhapur-416008 Maharashtra State(lndia)
2. COMPLETE SPECIFICATION
DESCRIPTION
The following specification particularly describes the invention and the manner in which it is to be performed.

TITLE
Diamino pyrimidine carbonitrile derivatives and their
Medicinal applications
Field of Invention:
Heterocyclic compounds occur widely throughout the nature; indeed, probably the majority of known organic compounds are heterocyclic in structure. The pyrimidine ring system occurs in thymine,cytosine,uracil, adenine and guanine which are component structures of nucleic acids and certain coenzymes.

Pyrimidine nucleosides have an important role in medicinal chemistry. Many antibiotics are nucleosides of pyrimidines which are effective in halting growth of cancer and can inhibit growth or destroy microorganisms ex.Puromycins.
Many pyrimidines of synthetic origin are widely used as therapeutic drugs, of these is a sulfonamide drug, sulfadiazine.Other class of pyrimidine medicinals are barbituric acid and phenobarbitals.

Literature is replete with medicinal uses of pyrimidines and purines.For instance 2, 6-dimercapto purines are used as anticancer agents.
References:
D.J.Brown, "The Pyrimidines" Wiley (Interscience), New York, 1962
T.L.V.Ulbricht, "Purines,Pyrimidines and Nucleotides" Pergamon, Oxford, 1964

PRIOR ART OF INVENTION
Diaminopyrimidine carbonitriles:
Among different derivatives of pyrimidines,the aminopyrimidines play very important role in the biological processes.The nucleic acids have pyrimidines in different forms.
The pyrimidine derivatives show profound physiological activities. Particularly the the pyrimidine carbonitriles show a wide spectrum of biological activity including antiviral,antibacterial,antitumor and antiinflammatory.
REFERENCES(Synthesis)
1. P.Biginelli, Gazz.Chim.Ital.,23,360,1893
2. C.O.Kappe, Tetrahedron,49,6937,1993
3. C.O.Kappe, Acc,Chem.Res.,33,879,200 ANTIBACTERIAL ACTIVITY
1 .T.Matsuda,I.Hirao,Nippon Kagaku Zasshi,86,l 195,1965
ANTI HIV ACTIVITY:
A.D.Patil et al. J.Org.Chem.,6,1182,1995
ANTI CANCER ACTIVITY
1. J.Med.Chem.,Vol.50,Nol9,Page 4728,2007
2 .E.N.Dozorova et al., Pharm.,19,154,1985
3 E.Buchdunger J.et al., Cancer Res.,56,100,1996

4. E.Maquoi et al., Clin,Cancer Res.,10,4038,2004
5. 5.M.Huang et al., Mol.Pharmacol,62,463,2002

STATEMENT OF INVENTION (OBJECT OF INVENTION)
There is ever present need for efficacious,nontoxic,with least side effects, drugs against a variety of human diseases. Alleviation of human sufferings has to be the primary aim of every scientific endevour, particularly in the fields of drug discovery.Towards this end an attempt is being made to provide novel drug molecules that have immense potential of treatment and cure against infectious diseases and deadly forms of cancer as also viral infections like HIV.

DESCRIPTION OF INVENTION IN DETAIL:
The compounds of following general formula/structure ( I ) have been prepared.
PROCEDURE FOR PREPARING COMPOUNDS OF GENERAL
FORMULA (I)

H2N N NH2
General structure / formula (I)
Suitably substituted benzaldehyde( 10 m mole ),malonitrile ( 10 mmole and potassium carbonate ( 1 gm ) were taken in a 500 ml round bottom flask with suitable quantity of water and agitated thoroughly. Then was added guanidine hydrochloride (20 m mole) and catalytic amount of tetrahydro butyl ammonium bromide (TBAB) and the contents were refluxed until the reaction was complete as indicated on TLC run.
On work up the desired product was obtained which was recrystallized

from a suitable combination of ethanol and water.
The structures of compounds were checked and confirmed by spectroscopic and physical characterization..
2,4-diamino-6-(4-hydroxy phenyl) pyrimidine-5-carbonitrile
IR 3308 cm -1,3210 cm-1 (OH and NH2),221a9cm-1(CN),1644cm-1,
1588cm-l(aromatic double bonds)
PMR singlet d 2.49,3.62 (two NH2 protons), doublet of doublet at
d 6.84 and another at d 7.23-8.04 (aromatic protons)
C13 NMR 75.1,115.1,122.8.130.1,133.8,157.8,158.9,160.5&113.9
Elemental Analysis C11H9 N5 O
Observed C 58.16%, H 4.00%, N 30.84%
Melting Point 260 degree centigrade

Structures and IUPAC Names of Compounds

IUPAC Chemical Names

Structure No

2.4-diamino-6-(2-hydroxy phenyl) pyrimidine-5-carbonitrile 1
2,4-diamino-6-(4-hydroxy phenyl) pyrimidine-5-carbonitrile 2
2,4-diamino-6-(3,4-dimethoxy phenyl) pyrimidine-5-carbonitrile 3
2,4-diamino-6-(4-methoxy phenyl) pyrimidine-5-carbonitrile 4
2,4-diamino-6-(4-chloro phenyl) pyrimidine-5-carbonitrile 5
2,4-diamino-6-(4-fluoro phenyl) pyrimidine-5-carbonitrile 6

BIOLOGICAL ACTIVITY PROFILE FOR THE COMPOUNDS:
Following Methods have been employed for screening for biological activities.
Antimicrobial activities were determined by the Microbroth Dilution Method ( NCCLS )
Anti Tubercular activities were determined against the H 37 Rv strain of M.tuberculosis
Cyto toxic effects was evaluated using the human HeLa cell line stfteured from the National Center For Cell Science,Pune
Anti retro viral tests for evaluation of anti HIV activity was performed by the Method of Viral Load by RT-PCR
The details of procedure are given in the following pages

Determination of Minimum Bactericidal Concentration:
Microbroth Dilution Method(NCCLS)
Materials and Reagents
Mueller-Hinton broth for performance of MIC test
1.0 and 0.5 McFarland turbidity standards
Scrupulously clean,acid washed borosilicate glass tubes
Vortex mixer
Eppendrof or similar micropipette
Nutrient agar plates.such as blood agar,for subculture fro broth
PROCEDURE
Preparation of Inoculation
Subcultured the test organism and quality contro organisms into
Appropriate medium(a blood agar plate)and incubated overnight at 35C Inoculate a tube that contains 2 ml of saline or Mueller-hinton broth With five or more colonies from the agar plate and adjust turbidity to Match a McFarland standard(approximately 10 CFU/ml) Transfer 0.1 ml of the turbid broth into 10 ml of Mueller-Hinton Broth,inoculate in shaking water bath or equivalent at 35C until Turbid(5 to 6 hours for rapid growth) .The relevant control organism Should be inoculated into 3 ml of broth and incubated without shaking Until turbid.This represents a midexponential phase of growth. Prepare twofold serial dilutions of the antibiotic in 2 ml of Mueller-Hinton broth.Use acid washed borosilicated glass tubes. Standardise the inoculum of the patients organism and the control

Strain by adjusting to a McFarland 0.5 standard in 3 ml of saline broth.
Dilute the adjusted inocula 1:10(approx 5X10 CFU/ml)
Using an Eppendorf or equivalent pipette,dispence 0.1 ml of the diluted
Inoculum intothe tubes that contain serial dilutions of antibiotic.Insert the
Tip well under the surface of the broth;avoid any contact between the tip and the walls of the tube.Rinse the tip five times.The same tip may be used
If the tubes are inoculated from the lower to higher concentration of the
antibiotic.The final inoculum size is approximately 2.5X10 CFU/ml.
incubate the tubes for 20 hours at 35C.
QUANTITATION OF THE INOCULUM
From the final dilution of the inoculum(approximately 5X10 CFU/ml)
perform four serial tenfold dilutions in Mueller-Hinton broths (final
Concentration of 5X10 CFU/ml).
In duplicate dispense 0.1ml onto the surface of a blood agar plate.Spread
the inoculum evenly with sterile bent glass rod.
incubate the plates overnight at 35C.
DETERMINATION OF MIC
After overnight incubation determine the MIC of quantity control strain by
virtual inspection of the tubes.
For the patient's sample only,vortex the tubes without growth vigorously
for 15 seconds to resuspend any bacteria that might have adhered to the
walls of the tube(avoid aerosols).
reincubate the tubes for additional four hours.

Determine the MIC of patient's sample by visual inspection of the tubes.
CONCLUSIONS:
The compounds of General Formula (I) have shown excellent activity
against Staph.Aureus,E-Coli.Klebsiella,Enterococcusfecalis.Antifungal
activity against Fluconazole Aspergillus and Candida albicas.

Anti T.B. tests
Anti tubercular activity was tested against H37 Rv strain of M.tuberculosis maintained in the laboratory.Middle brook 7H9 medium was prepared in bottles and starilised by autoclaving.ADC growth supplement containing bovine albumin fraction V,dextrose and catalase was added to each bottle with sterile precautions. A sterile suspension(10 mg/ml) of each compound to be tested was prepared using appropriate solvents under sterile conditions.Each compound was tested at a concentration say of 5 micro grams/ml and the required amount was added to each bottle of middle brook
medium.M.tuberculosis culture suspension was added at a concentration of 10 raise to 5 organisms per ml and the media were incubated at 37 degree centigrade in a humidified chamber for at least 4 weeks. Controls of antimycobacterial agents i.e. ciprofloxacin 5micro grams/ml,streptomycin 7.5 micro grams/ml and pyrazinamide 7.5 micro grams /ml were set up with each batch.A medium control and growth control tubes also were included.

Each bottle was examined periodically to observe for growth or contamination if any.At the end of four weeks a smear was prepared from each bottle showing turbidity stained with Z-N stain to confirm the presence of M.tuberculosis.Those media with the presence of organisms were considered as resistant to the compound and those without any bacteria were deemed as sensitive.
CONCLUSIONS:
The compounds of General Formula (I) have shown excellent activity against the H37 Rv strain of M.Tuberculosis.The lab results were further confirmed by field tests on Actual samples from patients.

Anti Cancer Tests
In vitro evaluation of cytotoxic effects on human tumour cell lines:
Cell culture. The HeLa cell line(procured from National Centre For Cell Science Pune
University,India)was maintained in the labs by serial sub cultures. The cell line was
maintained as mono layers in 75 cm square culture flasks in Eagles minimum essential
medium supplemented with 10% fetal calf serum 2mg of gentamicin, 100 Unit/ml of
penicillin and 100 micro gram/ml of streptomycin. The cells were grown in humidified
37 degree incubator with a regulated supply of 5% carbon dioxide. Medium was changed
every 5-6 days.
On the day of the experiment cells were washed with phosphate buffered saline and were detached from the surface of the flask by addition of 0.25% trypsin in EDTA buffer.The cells were then plated at a density of 5X10 to the power of 3 cells per well in 96 well micro plates containing 250 micro litre of cell culture medium per well and allowed to adhere over night. Stock solutions(10 micro gram per ml) of the compounds to be tested were freshly prepared just before use under sterile conditions. Each compound was tested in two concentration 10 and 100 micro grams per ml.Requisite amount of the compound was added to each well and were allowed to act on tumour cells for a period of 72 hours.

A cell control was also set up with each compound for comparison. At the end of the incubation period, each well was studied under 40X power inverted microscope and analyzed for cytotoxic effects of each concentration of the compound on tumour cell lines.
CONCLUSIONS:
The compounds of General Formula (I) have shown excellent anti cancer activity.The
Photographs are records of the cell growth inhibition.

WE CLAIM:
1. A process for the preparation of compounds of the general formula (I)

2. A process of the claim 1, wherein suitably substituted benzaldehyde (l0mmole), malonitrile (l0mmole), potassium carbonate (0.5 g) and water (40 ml) are mixed well;
3. A process of the claim 2, wherein guanidine hydrochloride (15mmole) and pinch of tetrabutyl ammonium bromide(TBAB) are added and refluxed.
4. A process of the claim 1, wherein the substituents are, as

Rl=H,OH,OMe,Cl,F,N02 etc. R2=H,OH,OMe,Cl etc R3=H,OH,C1 etc.
5. A method for inhibiting the growth of pathogenic microorganisms (ex: bacteria,fungi,M.tuberculum etc.) wherein the chemotherapeutic agent is a compound of general formula ( I ), its salt or a pharmaceutically acceptable form.
6. A method for inhibiting the growth/replication of any form of cancer (ex: tumor etc) wherein the chemotherapeutic agent is a compound of the general formula ( I ),its salt or a pharmaceutically acceptable form.
7. A method for inhibiting the replication of viruses (ex:HIV etc) wherein the chemotherapeutic agent is compound of the general formula ( I ),its salt or a pharmaceutically acceptable form.
8. A method for use as CNS stimulant( ex: Nootropic or Alzheimer
agent) wherein the chemotherapeutic agent is a compound of the
general formula ( I ),its salt or a pharmaceutically acceptable
form.

ABSTRACT
The present invention provides novel Diamino pyrimidine carbonitrile derivatives of general formula/structure ( I ) and a method for preparing general structure/compounds ( I.) The compounds,derivatives and analogs
thereof, are useful for treatment,management,or prevention of, or amelioration of one or more more symptoms of cancer, HIV , tuberculosis and other microbial and viral infections.

Documents:

534-MUM-2008-ABSTRACT(GRANTED)-(22-5-2012).pdf

534-mum-2008-abstract.doc

534-mum-2008-abstract.pdf

534-MUM-2008-CANCELLED PAGES(23-4-2012).pdf

534-MUM-2008-CLAIMS(AMENDED)-(19-7-2011).pdf

534-MUM-2008-CLAIMS(AMENDED)-(23-4-2012).pdf

534-MUM-2008-CLAIMS(GRANTED)-(22-5-2012).pdf

534-mum-2008-claims.doc

534-mum-2008-claims.pdf

534-MUM-2008-CORRESPONDENCE(23-4-2012).pdf

534-MUM-2008-CORRESPONDENCE(3-4-2012).pdf

534-MUM-2008-CORRESPONDENCE(IPO)-(22-5-2012).pdf

534-mum-2008-description (complete).pdf

534-MUM-2008-DESCRIPTION(GRANTED)-(22-5-2012).pdf

534-mum-2008-diagram.doc

534-MUM-2008-DRAWING(GRANTED)-(22-5-2012).pdf

534-mum-2008-drawings.pdf

534-MUM-2008-FORM 2(GRANTED)-(22-5-2012).pdf

534-MUM-2008-FORM 2(TITLE PAGE)-(COMPLETE)-(18-3-2008).pdf

534-MUM-2008-FORM 2(TITLE PAGE)-(GRANTED)-(22-5-2012).pdf

534-mum-2008-form 9(27-5-2008).pdf

534-mum-2008-form-1.pdf

534-mum-2008-form-18.pdf

534-mum-2008-form-2.doc

534-mum-2008-form-2.pdf

534-mum-2008-form-3.pdf

534-mum-2008-form-5.pdf

534-MUM-2008-REPLY TO EXAMINATION REPORT(19-7-2011).pdf

abstract1.jpg

« Previous Patent

Next Patent »

Patent Number

252551

Indian Patent Application Number

534/MUM/2008

PG Journal Number

21/2012

Publication Date

25-May-2012

Grant Date

22-May-2012

Date of Filing

18-Mar-2008

Name of Patentee

SHELAR ASHOK RANGANATH

Applicant Address

PLOT NO.8, UNIT NO.1, AMBAI DEFENCE COLONY, KOLHAPUR- 416008,

Inventors:

#	Inventor's Name	Inventor's Address
1	SHELAR ASHOK RANGANATH	PLOT NO.8, UNIT NO.1, AMBAI DEFENCE COLONY, KOLHAPUR 416008.
2	SHELAR MILIND ASHOK	MILIND SHELAR(PH.D) IPER PLOT NO.8, UNIT NO.1, AMBAI DEFENCE COLONY, KOLHAPUR 416008.
3	SHELAR BALKRISHNA ASHOK	B.A.SHELAR(PH.D) IPER PLOT NO.8, UNIT NO.1, AMBAI DEFENCE COLONY, KOLHAPUR 416008.

PCT International Classification Number

A61K31/505,C07D239/50

PCT International Application Number

N/A

PCT International Filing date

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1			NA